Large-scale radiomic profiling of glioblastoma identifies an imaging signature for predicting and stratifying antiangiogenic treatment response
P Kickingereder, P Kickingereder, M Götz, J Muschelli, A Wick, U Neuberger, R Shinohara, A Radbruch, H Schlemmer, W Wick, M Bendszus, K Maier-Hein, D Bonekamp · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 2016 · Heft 03
Bibliografische Angaben
Zusammenfassung
Zielsetzung: Antiangiogenic treatment with bevacizumab is the single most widely used therapeutic agent for patients with recurrent glioblastoma (GB). A major challenge is that there are currently no validated biomarkers that can delineate molecular activity and predict treatment response. Here we analyze the potential of radiomics, an emerging field of research that aims to utilize the full potential of medical imaging. Material und Methodik: A total of 4842 quantitative MRI features (including first-order, volume and shape features and texture features) were automatically extracted from the complete three-dime…
